Monaco Asset Management SAM Takes Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Monaco Asset Management SAM bought a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 311,210 shares of the company's stock, valued at approximately $2,038,000. Monaco Asset Management SAM owned 0.12% of Maravai LifeSciences at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Gladius Capital Management LP bought a new position in shares of Maravai LifeSciences during the 4th quarter worth approximately $30,000. Performa Ltd US LLC lifted its position in shares of Maravai LifeSciences by 112.4% during the 4th quarter. Performa Ltd US LLC now owns 6,000 shares of the company's stock valued at $39,000 after acquiring an additional 3,175 shares during the period. National Bank of Canada FI boosted its stake in Maravai LifeSciences by 509,962.5% during the fourth quarter. National Bank of Canada FI now owns 204,025 shares of the company's stock worth $1,375,000 after acquiring an additional 203,985 shares in the last quarter. M&T Bank Corp increased its stake in Maravai LifeSciences by 17.3% in the fourth quarter. M&T Bank Corp now owns 20,107 shares of the company's stock valued at $131,000 after purchasing an additional 2,972 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of Maravai LifeSciences by 237.4% during the fourth quarter. Victory Capital Management Inc. now owns 110,468 shares of the company's stock valued at $724,000 after purchasing an additional 77,727 shares during the period. Institutional investors and hedge funds own 50.25% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Robert W. Baird increased their price target on Maravai LifeSciences from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Thursday. Craig Hallum assumed coverage on shares of Maravai LifeSciences in a research report on Wednesday, April 10th. They issued a "buy" rating and a $15.00 price target for the company. Royal Bank of Canada raised their price objective on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the company an "outperform" rating in a research note on Friday, February 23rd. Finally, Stifel Nicolaus decreased their target price on shares of Maravai LifeSciences from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, February 23rd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $11.44.

Maravai LifeSciences Stock Performance

MRVI stock traded up $0.60 during mid-day trading on Friday, hitting $10.46. The company had a trading volume of 3,834,160 shares, compared to its average volume of 1,839,233. Maravai LifeSciences Holdings, Inc. has a 12 month low of $4.52 and a 12 month high of $16.62. The stock's fifty day moving average price is $8.19 and its two-hundred day moving average price is $6.78. The firm has a market cap of $2.63 billion, a PE ratio of -10.57 and a beta of 0.03. The company has a debt-to-equity ratio of 0.70, a quick ratio of 7.41 and a current ratio of 8.00.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Maravai LifeSciences had a negative net margin of 47.81% and a negative return on equity of 4.17%. The firm had revenue of $74.14 million during the quarter, compared to analysts' expectations of $62.99 million. On average, analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.15 earnings per share for the current fiscal year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.